Block Listing Return

Diaceutics PLC

07 October 2026

 

Diaceutics PLC

BLOCK LISTING RETURN

New York, Belfast and London, 7 October 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long term incentive awards.

Name of applicant:		Diaceutics PLC
Name of scheme:		UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long-term incentive awards.
Period of return:	From:	7 April 2026	To:	6 October 2026
Balance under scheme from previous return:		1,233,063 Ordinary Shares of £0.002 each
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		N/A
Number of securities issued/allotted under schemes during period:		316,969 Ordinary Shares
Balance under scheme not yet issued/allotted at end of period		916,094 Ordinary Shares
Number and class of securities originally listed and the date of admission		1,500,000 Ordinary Shares on 6 October 2023
Total number of securities in issue at the end of the period		85,234,252 Ordinary Shares of £0.002 each
Name of contact:		Nick Roberts
Telephone number of contact:		As below

Enquiries: 

Diaceutics PLC
Nick Roberts, Chief Financial Officer	Tel: [phone] [e-mail]
Canaccord Genuity Limited (Nomad & Broker)	Tel: [phone]
Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

 

END